drugset

drugset / Trial / NCT00639678

A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects

NCT00639678 ↗

Phase 3 Completed 322 enrolled Human Genome Sciences Inc. Emergent BioSolutions · collab GlaxoSmithKline · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the safety and tolerability of raxibacumab in healthy subjects.

Timeline

Start: 2008-03
Primary completion: 2008-07
Completion: 2008-09

Publications

Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009 Jul 9;361(2):135-44. doi: 10.1056/NEJMoa0810603.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Raxibacumab	Monoclonal antibody	40 mg/kg	Intravenous

Indications

No indication recorded.